Search

Our study explores the current state of machine learning (ML) as applied to predicting and designing organic photovoltaic (OPV) devices. We outline key considerations for selecting the method of encoding a molecular structure and selecting the algorithm while also emphasizing important aspects of training and rigorously evaluating ML models. This work presents the first comprehensive dataset of OPV device fabrication data mined from the literature. The top models achieve state-of-the-art predictive performance. In particular, we identify an algorithm that is used less frequently, but may be particularly well suited to similar datasets. However, predictive performance remains modest (R2 ≅ 0.6) overall. An in-depth analysis of the dataset attributes this limitation to challenges relating to the size of the dataset, as well as data quality and sparsity. These aspects are directly tied to difficulties imposed by current reporting and publication practices. Advocating for standardized reporting of OPV device fabrication data reporting in publications emerges as crucial to streamline literature mining and foster ML adoption. This comprehensive investigation emphasizes the critical role of both data quantity and quality, and highlights the need for collective efforts to unlock ML's potential to drive advancements in OPV. [ABSTRACT FROM AUTHOR]

Replacement therapy using recombinant factor VIII (rFVIII) is currently the most common therapy for hemophilia A, a bleeding disorder caused by the deficiency of FVIII. However, 15--30% of patients develop inhibitory antibodies against administered rFVIII, which complicates the therapy. Encapsulation or association of protein with lipidic structures can reduce this immune response. Previous studies developed and characterized rFVIII-containing phosphatidylserine (PS) cochleate cylinders using biophysical techniques. It was hypothesized that these structures may provide a reduction in immunogenicity while avoiding the rapid clearance by the reticuloendothelial system (RES) previously observed with liposomal vesicles of similar composition. This study investigated in vivo behavior of the cochleates containing rFVIII including immunogenicity and pharmacokinetics in hemophilia A mice. The rFVIII-cochleate complex significantly reduced the level of inhibitory antibody developed against rFVIII following intravenous (i.v.) administration. Pharmacokinetic modeling allowed assessment of in vivo release kinetics. Cochleates acted as a delayed release delivery vehicle with an input peak of cochleates showed limited RES uptake and associated rFVIII displayed a similar disposition to the free protein upon release from the structure. Incomplete disassociation from the complex limits systemic availability of the protein. Further formulation efforts are warranted to regulate the rate and extent of release of rFVIII from cochleate complexes. [ABSTRACT FROM AUTHOR]